APeX-2
15 evidence topics · 4 sources
Objective
Location and study date
Study design
Eligibility criteria
Run-in attack requirement
Treatment
Berotralstat 110-mg and 150-mg regimens: route and administration
Study outcomes
Rationale for using monthly HAE attack rate as the primary endpoint
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Randomized and treated populations
| Population | Participants |
|---|---|
| Randomized | “121”View highlighted excerpt for this quote |
| Berotralstat 110 mg treated | “41”View highlighted excerpt for this quote |
| Berotralstat 150 mg treated | “40”View highlighted excerpt for this quote |
| Placebo treated | “39”View highlighted excerpt for this quote |
Description of analysis sets
Results
Participant disposition
Treatment exposure
| Population | Participants |
|---|---|
| Received at least one dose | “120”View highlighted excerpt for this quote |
Baseline characteristics
Median baseline attack rate during the prospective run-in period
Efficacy results
Monthly attack rates during the 24-week comparison
| Treatment | Attacks per month |
|---|---|
| Berotralstat 110 mg | “1.65”View highlighted excerpt for this quote |
| Berotralstat 150 mg | “1.31”View highlighted excerpt for this quote |
| Placebo | “2.35”View highlighted excerpt for this quote |
Health-related quality of life and patient-reported outcomes
AE-QoL total score at week 24 in APeX-2
“In both APeX‐2 and APeX‐J, 43% of patients receiving berotralstat 150 mg achieved minimal clinically important difference (MCID) in Angioedema QoL (AE‐QoL) total score, compared with 17% in the placebo group at 6 months” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“least square mean difference [LSMD] of change from baseline: −4.9 in APeX‐2 [p = 0.188]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pooled APeX-2 and APeX-J post hoc analysis: AE-QoL at week 24
“We conducted a post hoc trial analysis to evaluate the impact of berotralstat on HRQoL versus placebo through 24 weeks, and the long‐term effects of treatment up to 96 weeks, using pooled APeX‐2 and APeX‐J patient data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 47 patients treated with berotralstat (40 from APeX‐2; 7 from APeX‐J) and 45 treated with placebo (39 from APeX‐2; 6 from APeX‐J) were included in the analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At Week 24, patients receiving berotralstat demonstrated significantly greater improvement versus placebo in AE‐QoL total (LSMD: −7.4; 95% CI: −14.3, −0.6; p < 0.05), functioning domain (LSMD: −10.9; 95% CI: −19.6, −2.3; p = 0.013), and fears/shame domain (LSMD: −8.7; 95% CI: −17.2, −0.2; p = 0.046) scores.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Open-label extension: quality of life through 96 weeks
“Secondary endpoints included HAE attack rates and quality of life (QoL).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Clinically meaningful improvements in QoL were also observed, with the largest improvements in the functioning domain.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Safety results
Serious treatment-emergent adverse events considered drug related
Study limitations
Summary
The trial randomized 121 participants at 40 sites in 11 countries and treated 120: 41 received berotralstat 110 mg, 40 received berotralstat 150 mg, and 39 received placebo. Eligibility required “at least two investigator-confirmed attacks” during the run-in period, and the median baseline attack rate was 2.9 attacks per month. Efficacy was analyzed in the intent-to-treat population with a “negative binomial regression model”. The comparison does not describe outcomes over longer treatment, and groups of 39 to 41 participants limit precision for uncommon adverse events. No health-related quality of life result for this trial was identified. Berotralstat was compared with placebo only. Comparison with other prophylactic agents therefore relies on cross-trial comparison, in which differences in eligibility, baseline attack rates, and observation periods can affect the reported attack rates.